CL2014003173A1 - Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona - Google Patents
Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetonaInfo
- Publication number
- CL2014003173A1 CL2014003173A1 CL2014003173A CL2014003173A CL2014003173A1 CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1 CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A CL2014003173 A CL 2014003173A CL 2014003173 A1 CL2014003173 A1 CL 2014003173A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- glucocorticoid receptor
- fused azadecalin
- heteroaryl ketone
- azadecalin glucocorticoid
- Prior art date
Links
- 102000003676 Glucocorticoid Receptors Human genes 0.000 title 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
- -1 heteroaryl ketone Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electroluminescent Light Sources (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003173A1 true CL2014003173A1 (es) | 2015-02-27 |
Family
ID=49624542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003173A CL2014003173A1 (es) | 2012-05-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona |
Country Status (24)
| Country | Link |
|---|---|
| EP (6) | EP3590517B1 (enExample) |
| JP (1) | JP6172871B2 (enExample) |
| KR (1) | KR102062640B1 (enExample) |
| CN (1) | CN104619328B (enExample) |
| AU (1) | AU2013266110C1 (enExample) |
| BR (1) | BR112014028857B1 (enExample) |
| CA (1) | CA2872260C (enExample) |
| CL (1) | CL2014003173A1 (enExample) |
| DK (5) | DK3590517T3 (enExample) |
| ES (5) | ES2995026T3 (enExample) |
| FI (1) | FI4119561T3 (enExample) |
| HK (1) | HK1250014B (enExample) |
| IL (1) | IL235868A (enExample) |
| MX (1) | MX365423B (enExample) |
| MY (1) | MY172739A (enExample) |
| NZ (1) | NZ701469A (enExample) |
| PE (1) | PE20150352A1 (enExample) |
| PH (1) | PH12014502584B1 (enExample) |
| PL (5) | PL3851107T3 (enExample) |
| PT (5) | PT3338781T (enExample) |
| RU (1) | RU2639867C2 (enExample) |
| SG (1) | SG11201407682TA (enExample) |
| WO (1) | WO2013177559A2 (enExample) |
| ZA (1) | ZA201408182B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12648943B2 (en) | 2020-01-29 | 2026-06-09 | Corcept Therapeutics Incorporated | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2943542T3 (es) * | 2013-11-25 | 2023-06-14 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| JP6821582B2 (ja) * | 2015-03-02 | 2021-01-27 | コーセプト セラピューティクス， インコーポレイテッド | Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用 |
| JP6754533B2 (ja) | 2015-03-30 | 2020-09-16 | コーセプト セラピューティクス， インコーポレイテッド | 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用 |
| US10604807B2 (en) | 2015-05-18 | 2020-03-31 | Corcept Therapeutics, Inc. | Methods for diagnosing and assessing treatment for Cushing's syndrome |
| MX383318B (es) * | 2015-08-13 | 2025-03-13 | Corcept Therapeutics Inc | Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina. |
| AU2017228329B2 (en) * | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| WO2018236749A2 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| IL278125B (en) * | 2018-04-23 | 2022-09-01 | Corcept Therapeutics Inc | Methods for the preparation of regioselective n-alkyl triazoles |
| SG11202104732UA (en) | 2018-11-09 | 2021-06-29 | Corcept Therapeutics Inc | Methods for shrinking pituitary tumors |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| MX2021007402A (es) * | 2018-12-20 | 2021-07-15 | Corcept Therapeutics Inc | Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina. |
| NZ778399A (en) | 2019-02-22 | 2024-11-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| AU2020367769B2 (en) * | 2019-10-16 | 2023-10-12 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| AU2020408057B2 (en) * | 2019-12-21 | 2026-01-29 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, ACTH-Dependent Cushing's syndrome and ACTH-Independent Cushing's syndrome |
| JP2023515781A (ja) * | 2020-02-10 | 2023-04-14 | コーセプト セラピューティクス， インコーポレイテッド | 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法 |
| MX2022014923A (es) | 2020-05-27 | 2023-01-04 | Corcept Therapeutics Inc | Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9. |
| EP4157276A4 (en) | 2020-05-27 | 2024-06-12 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| TW202246260A (zh) * | 2021-02-03 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 |
| CN114907340A (zh) * | 2021-02-09 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907349B (zh) * | 2021-02-10 | 2026-06-12 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| WO2024077169A1 (en) * | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| AU2024223250A1 (en) * | 2023-02-17 | 2025-08-14 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
| WO2026132432A1 (en) | 2024-12-20 | 2026-06-25 | Curia Spain, S.A.U. | Relacorilant crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP4931794B2 (ja) * | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス， インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| US7640389B2 (en) * | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| BR112013004322A2 (pt) * | 2010-08-27 | 2016-06-21 | Corcept Therapeutics Inc | moduladores de azadecalin fundidos com piridil-aminas |
-
2013
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en not_active Ceased
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 ES ES22193438T patent/ES2995026T3/es active Active
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 DK DK22193438.3T patent/DK4119561T3/da active
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 EP EP24192650.0A patent/EP4434584A3/en active Pending
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 PL PL22193438.3T patent/PL4119561T3/pl unknown
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
- 2013-05-24 EP EP22193438.3A patent/EP4119561B1/en active Active
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 PT PT221934383T patent/PT4119561T/pt unknown
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active Active
- 2013-05-24 FI FIEP22193438.3T patent/FI4119561T3/fi active
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584B1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12648943B2 (en) | 2020-01-29 | 2026-06-09 | Corcept Therapeutics Incorporated | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4119561T3 (da) | Heteroaryl-ketonkondenserede azadecalin-glucocorticoidreceptormodulatorer | |
| ZA201604026B (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| ZA201604703B (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| SMT201700009B (it) | Modulatori del recettore x del fegato | |
| DK2964229T3 (da) | Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren | |
| SMT201600374B (it) | Modulatori del recettore x del fegato | |
| IL242782B (en) | cxcr7 receptor modulators | |
| CO7190237A2 (es) | Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona | |
| ITMI20120786A1 (it) | Modulatori del recettore gpr17 |